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Abstract:   
 
The killing activity of daptomycin against an isogenic pair of daptomycin susceptible and 
daptomycin non-susceptible (DNS) MRSA strains was enhanced by the addition of 
certain cell wall agents at 1xMIC concentrations. However, when high inocula of DNS 
were used, no significant killing was observed in our experiments. Cytochrome c binding 
assays revealed D-cycloserine as the only agent associated with a reduction in the cell 




The mechanisms of resistance to daptomycin in Staphylococcus aureus have been related 
to  cell membrane alterations; cell wall thickening, modifications in membrane lipid 
composition, altered drug binding and changes in the surface charge (1).  
Almost all synthesis of (the positively charged) D-alanine in S. aureus is controlled by 
alanine racemase (2,3). D-cycloserine (DCS) is a D-alanine analog used as a second-line 
treatment for mycobacterial infections. It prevents peptidoglycan synthesis in bacterial 
cell wall by a competitive inhibition of both alanine racemase and D-alanine ligase 
enzymes (4,5)  
The aim of this study was to ascertain the effect of DCS, in comparison to other cell wall 
agents (CWA), on the activity of daptomycin against MRSA and to assess related 
variations in cell surface charge. For this purpose, an isogenic pair of MRSA strains from 
an episode of bacteremia and osteomyelitis treated with daptomycin was used: the 
daptomycin-susceptible progenitor, A8796 (DS) and the daptomycin-non susceptible 
derivative, A8799 (DNS), which harbored an mprF mutation (S337L) (6).  
Daptomycin (Cubist Pharmaceuticals, Inc, Lexington, MA) and CWA were used in this 
study: vancomycin (VAN), ampicillin (AMP), oxacillin (OXA), cefazolin (CFZ), 
imipenem (IMI), fosfomycin (FOM) and D-cycloserine (DCS) (Sigma-Aldrich 
Corporation, St.Louis MO). For all experiments the purified powder of each antibiotic 
was resuspended following the CLSI recommendations (7).  
Determination of Minimum inhibitory concentrations (MICs) and studies of 
daptomycin susceptibility. MICs of daptomycin, DCS and FOM were determined by 
broth macrodilution method according to standard recommendations (7). MICs of all 
other antibiotics were determined by the E-test (AB BioMerieux, Solna, Sweden), 
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according to the manufacturer’s instructions (Table 1). A see-saw effect (8,9) between the 
DAP MIC (increased) and the MICs of beta-lactams (decreased) was observed for the 
isogenic isolates (Table 1). Although this phenomenon is not completely understood, it 
might be related to an alteration of mecA gene regulation in the DNS isolates (9).  
48-hour time-kill curves (TKC) were performed following standard methodology (10). 
Standard inoculum (106CFU/ml) and high inoculum (108CFU/ml) of bacteria were used. 
In order to mimic clinically-relevant serum concentrations, 8 µg/mL (D8) of DAP were 
used in all experiments (11), either alone or in combination with CWA  at prefixed 
concentrations of 1xMIC. Daptomycin alone and all the CWA showed no net killing 
activity at 48 hours against both strains. Against standard inoculum DS the addition of all 
CWA to DAP produced greater killing compared to D8 alone, but bactericidal activity 
was only maintained at 48h with the combinations OXA+D8 (Δ-3.93log), DCS+D8 (Δ-
3.85log) and CFZ+D8 (Δ-3.17log). Bacterial regrowth at 48 hours was only prevented by 
the combinations DCS+D8 and OXA+D8 (Figure 1A). Against high inoculum DS 
bactericidal activity at 24h was only maintained at 48h with the combinations OXA+D8 
(Δ-4.73log), DCS+D8 (Δ-5.85log) and IMI+D8 (Δ-4.64log) but regrowth was only 
prevented by the combination DCS+D8 (Figure 1B). Against standard inoculum DNS, 
the only combinations that prevented regrowth at 48 hours were OXA+D8 (Δ-3.80log), 
IMI+D8 (Δ-3.66log) and DCS+D8 (Δ-3.77log) (Figure 1C). As shown in figure 1D, 
against high inoculum DNS, synergy was not observed with any combination. In 
summary, at the concentrations used OXA, DCS and IMI had a comparable effect on 
daptomycin killing, there being synergistic or additive activity with D8 in three of the 
experiments (with the exception of DNS at initial high inoculum). However, DCS+D8 
did not allow regrowth at 48 hours in any of those three experiments, and was the only 
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combination achieving net killing against the DNS strain at initial high inoculum (Δ-
0.48log).  As far as we know, this is the first time that DCS+daptomycin activity has been 
tested against MRSA. Synergism between daptomycin and beta-lactams or fosfomycin 
has been previously observed (12-15) and is further supported from our experiments.  
Evaluation of bacterial surface charge (16). After overnight growth in trypticase soy 
broth (TSB), cultures were resuspended in fresh medium containing one CWA at 1xMIC. 
It was then resuspended in fresh medium containing the positively charged molecule 
cytochrome c (CyC) from bovine heart (Sigma). The optical density (A405) of the 
supernatant was measured (SPECTRAmax Plus 384, Molecular Devices Corporation, 
Sunnyvale, CA) and the total amount of cell-bound CyC was obtained using a standard 
curve. Experiments were repeated 4 times. Analysis of variance test with the post hoc 
Bonferroni correction were used to determine differences in the bound CyC means in the 
presence of various antibiotics. Differences were considered statistically significant when 
P values were ≤0.05. In the absence of antibiotic exposure, significant differences 
(p<0.05) were found between the amount of CyC bound to A8796 (1.39mg+ 0.07) and 
A8799 (1.22mg+0.09) (Figures 2A and 2B). For both strains, the amount of CyC bound 
in the presence of DCS at 1xMIC was significantly higher compared to that bound in its 
absence (1.26-fold increase for A8796 and 1.68-fold increase for A8799). We 
hypothesize that the reduction in D-alanine synthesis achieved by DCS may be related to 
the reduction in the cell surface charge, signified by the increased CyC binding. As 
observed in figure 2B, for A8799 there were also significant differences regarding CyC 
binding in the presence of CFZ (1.21-fold increase) and FOM (1.09-fold increase), which 
might be strain-dependent. Also, since FOM inhibits the uridine diphosphate (UDP)-N-
acetylglucosamine enolpyruval transferase, these results stress the concept that reduction 
 6
in the envelope charge is not specific to the mechanism of action of either DCS or the 
beta-lactams. They also suggest that mechanisms additional to surface charge changes are 
likely to be involved into synergism between CWA and daptomycin. Finally, our results 
highlight the importance of the bacterial inoculum for daptomycin efficacy and the 
difficulties to reach its targets in high bacterial density (17-19). This study has some 
limitations. Given the profound see-saw effect observed with the beta-lactams, their 
concentrations used against the DNS isolate were lower than those clinically achievable. 
The potential neurotoxicity and contraindication of DCS in severe renal impairment could 
severely limit its clinical use in treating severe MRSA infections. Nonetheless, this study 
does suggest a way of overcoming MRSA daptomycin resistance and opens the door to 
further research, based on reducing cell wall D-alanine composition, by inhibiting alanine 
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Table 1: Daptomycin and cell wall agents’ minimum inhibitory concentrations (MIC) of a 




(*) MICs were determined two times. It was not detected significant increase in MIC at 48 hours with respect to that read at 24 hours, 
for any of the antibiotics tested.  
 
MIC (µg/mL) (*) 
 
Daptomycin Vancomycin Ampicillin Oxacillin Cefazolin Imipenem Fosfomycin D-cycloserine 
A8796  0.5 1 16 512 128 64 2 32 
A8799  2 2 6 0.38 32 0.094 1 32 


